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Abstract
Respiratory tract infections (RTI) are more commonly caused by viral pathogens in children than in adults. Surprisingly, little is
known about antibiotic use in children as compared to adults with RTI. This prospective study aimed to determine antibiotic
misuse in children and adults with RTI, using an expert panel reference standard, in order to prioritise the target age population for
antibiotic stewardship interventions. We recruited children and adults who presented at the emergency department or were
hospitalised with clinical presentation of RTI in The Netherlands and Israel. A panel of three experienced physicians adjudicated
a reference standard diagnosis (i.e. bacterial or viral infection) for all the patients using all available clinical and laboratory
information, including a 28-day follow-up assessment. The cohort included 284 children and 232 adults with RTI (median age,
1.3 years and 64.5 years, respectively). The proportion of viral infections was larger in children than in adults (209(74%) versus
89(38%), p < 0.001). In case of viral RTI, antibiotics were prescribed (i.e. overuse) less frequently in children than in adults (77/
209 (37%) versus 74/89 (83%), p < 0.001). One (1%) child and three (2%) adults with bacterial infection were not treated with
antibiotics (i.e. underuse); all were mild cases. This international, prospective study confirms major antibiotic overuse in patients
with RTI. Viral infection is more common in children, but antibiotic overuse is more frequent in adults with viral RTI. Together,
these findings support the need for effective interventions to decrease antibiotic overuse in RTI patients of all ages.
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Introduction
Acute respiratory tract infections (RTIs) are one of the leading
causes of emergency department (ED) visits and are often due to
viral pathogens [1–4]. Although viral infections are more com-
mon in children, studies based on national datasets show that the
problem of antibiotic overuse in RTI is largest in adults [4–6].
Unfortunately, it is often not possible to differentiate between
viral and bacterial diseases on clinical judgment alone [7].
Antibiotic overuse is associated with an increasing prevalence
of antibiotic resistance [8]. In Europe, 25,000 patients die annu-
ally due to infections with antibiotic-resistant microorganisms,
with estimated costs of €1.5 billion [9–11]. Therefore, there are
increasing efforts to study host-biomarkers that could discrimi-
nate bacterial from non-bacterial infections [12]. A prospective,
international study (The “TAILORED Treatment” (TTT) study)
was designed to generate a multi-parametric model for
distinguishing between bacterial and viral infections based on
new host- or pathogen-related biomarkers [13]. As a gold stan-
dard to diagnose bacterial infections is missing, this study used
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an expert panel reference standard to diagnose each individual
patient. Most studies that evaluated antibiotic misuse rates are
based on national datasets and classify infections, using general
codes, such as the International Classification of Diseases [4–6].
Using guidelines for assessing antibiotic misuse can result in
contradictory analyses. For example, Donnelly et al. [4] have
classified pharyngitis and tonsillitis as diseases for which antibi-
otic treatment is appropriate, whereas Barlam et al. [5] have
proposed that antibiotic use for these illnesses is inappropriate.
Using an expert panel as reference standard has the advantage of
individual outcomes (i.e. bacterial or viral infection) for every
patients, resulting in more accurate percentages of antibiotic mis-
use. The current prospective study is aimed to determine antibi-
oticmisuse in children and adults with RTI, using an expert panel
reference standard. This study will be instrumental to analyse
strategies for new diagnostics to differentiate between viral and
bacterial infections.
Material and methods
Study design
Patient recruitment for this prospective biomarker TTT-study
took place in convenience and consecutive series at the ED
and wards of secondary and tertiary hospitals in
The Netherlands and Israel [13]. For this subgroup analyses,
paediatric patients (aged ≥ 1 month) and adult patients (aged
> 18 years), with a suspected upper and/or lower RTI and a
maximal disease duration of 8 days, were selected. RTI was
defined as presence of two or more of the following signs:
tachypnea, cough, nasal flaring, chest retractions, rales, expi-
ratory wheeze and/or decreased breath sounds. For children,
WHO age-specific criteria for tachypnea were used [14].
Patients were excluded in case of: previous episode of fever
in the past 3 weeks; nosocomial RTI (> 3 days after
hospitalisation); psychomotor retardation; moderate-to-
severe metabolic disorder; primary or secondary immunode-
ficiency; proven or suspected HIV, HBV, or HCV infection;
and active malignancies. Patients who received antibiotics at
any time before the beginning of the study were not excluded.
To participate in the study (parental), informed consent was
required. The TTT-study is registered on ClinicalTrials.gov,
NCT02025699, and was approved by the ethics committees
in the participating countries.
Data collection
Data collection of this TTT-study was described previously [13].
In short, all available clinical data (including biomarkers tested
for routine care, a study specific nasal swab and information from
a 28-day follow-up assessment) was recorded in an electronic
Case Report Form (eCRF) [13]. A multiplex PCR-based assay
of the 14 most common respiratory pathogens (nine viruses, five
bacteria) was performed on all nasal swabs (MagnaPure LC total
nucleic acid kit and MagnaPure 96 DNA, Roche Diagnostics,
Mannheim, Germany) [15]. The PCR results were not available
for the attending physician, since this assay was performed after
completion of the recruitment process.
Outcomes
Currently, no single reference standard test exists for deter-
mining the aetiology of an infection [16]. Therefore, we
followed the UK’s National Health Service standard for eval-
uating diagnostic tests and employed an expert panel reference
standard [17]. As described previously, we established expert
panels with experienced paediatricians for the paediatric co-
hort and specialists in internal medicine, pulmonology and
infectious diseases for the adult cohort [13]. Every recruited
patient was diagnosed by three panel members, and each ex-
pert assigned one of the following classifications to each pa-
tient: viral infection; bacterial infection; mixed infection (i.e.
viral and bacterial co-infection); non-infectious disease; or
indeterminate. A majority consensus was applied for the final
diagnosis. Patients assigned as ‘mixed infection’ were subse-
quently classified as bacterial because they are clinically man-
aged similarly. Cases were labelled as ‘inconclusive’ if each
panel member assigned a different aetiology or when at least
two panel members diagnosed the case as ‘indeterminate’. A
microbiologically confirmed diagnosis was predefined as a
unanimous panel diagnosis plus the detection of at least one
virus for viral cases or for bacterial cases a positive blood
culture, excluding the following probable contaminants:
coagulase-negative staphylococci; Corynebacterium spp.;
Bacillus spp.; Propionibacterium acnes; Micrococcus spp.;
and Viridans group streptococci. For the detection of viruses
and bacteria microbiological diagnostics performed for rou-
tine care (e.g. blood cultures, sputum cultures and serology)
and study, specific nasal swab PCR results were reviewed.
Statistical analysis
Patients from this convenience cohort of the TTT biomarker
study were first stratified according to the reference diagnosis
(e.g. viral, bacterial, non-infectious and inconclusive). For the
purpose of this study, we excluded non-infectious and inconclu-
sive cases. For the primary objective of this study, we then cal-
culated and compared the percentage of antibiotic use per refer-
ence diagnosis for children and adults separately. A sensitivity
analysis was performed on the microbiologically confirmed sub-
cohort. Secondary analyses were performed for children and
adults separately to compare patient characteristics between viral
and bacterial infections, antibiotic use per virus, patient charac-
teristics of viral cases receiving and not-receiving antibiotics and
different antibiotic agents per country. Sub-cohort analyses were
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performed for the Dutch and Israeli cohorts separately and for
patients admitted to the intensive care unit (ICU). A post hoc
analysis was performed on the timing of antibiotic administration
in patients with bacterial outcomes to see whether there is de-
layed antibiotic prescribing (i.e. antibiotics started > 72 h after
admission). For baseline characteristics, univariate comparisons
were performed using the Fisher exact test, the Student t test, and
Mann-Whitney test, as appropriate. Statistical analysis was per-
formed using the SPSS version 22.0 for Windows software. A p
value < 0.05 was considered statistically significant.
Results
Patient characteristics
Between April 2014 and September 2016, a total of 616 pa-
tients with RTI (302 children and 314 adults) were recruited
(Fig. 1). The panel diagnosed 516 patients as having a bacte-
rial or a viral infection, encompassing 284 children and 232
adults (median ages, 1.3 years and 64.5 years, respectively)
(Table 1). The expert panel diagnosed 12 adults as having a
non-infectious disease (predominantly, chronic obstructive
pulmonary disease or asthma exacerbation). The reference
standard diagnosis was inconclusive for 18 (4 Dutch, 14
Israeli) children and 70 (26 Dutch, 44 Israeli) adults. In 44%
of the children with bacterial and viral RTI had comorbidity and
not 'bacterial and viral RTI comorbiditis, most of them had mild
diseases (e.g. allergies, hyper-reactive airway and eczema). In
adults, comorbidity was seen more often (86%) and chronic dis-
eases were more diverse (e.g. cardiovascular risk factors, neuro-
logical complaints, pulmonary or cardiac problems). In 215
(76%) children and 120 (52%) adults, the study nasal swab (to
help the expert panel establishing the outcome) was positive for
one or more microorganisms (Supplemental Table 1). In most of
the patients with a bacterial reference standard, a bacterial patho-
genwas not found (Supplemental Table 1). The study nasal swab
was performed in all patients. Therefore, routine care identified
significantly fewer pathogens compared to the study swab.
Patient outcomes
The proportion of viral infections was larger in children than in
adults (209/284 (74%) versus 89/232 (38%), respectively,
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Fig. 1 Flowchart of patients AB− antibiotics not prescribed, AB+ antibiotics prescribed, RTI respiratory tract infection, AAU appropriate antibiotic use,
IAU inappropriate antibiotic use
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p < 0.001). Most bacterial co-infections were observed in chil-
dren infected with rhinovirus (17/62, 27%) and respiratory syn-
cytial virus (RSV) (23/98, 23%), whereas influenza was most
frequently associated with bacterial co-infection in adults (17/
52, 33%, Table 2). Children and adults with bacterial infections
were more often hospitalised (p values respectively < 0.0001 and
0.009) and had higher CRP values (p value 0.001 and < 0.0001
respectively) compared with patients with a viral infection
(Table 3). In 172/284 (61%) of the paediatric cohort and 114/
232 (49%) of the adult patients, the expert panel diagnosis can be
confirmed microbiologically. This microbiologically confirmed
sub-cohort includes in total 286 patients, 145 children and 58
adults with viral infection and 27 children and 56 adults with
bacterial infection (Supplemental Fig. 1).
Antibiotic usage
The overall antibiotic prescription rate for viral and bacterial
RTI was 71%, and the antibiotic overuse rate (i.e. antibiotic
prescription for viral RTI) was 51%. Antibiotics were admin-
istered less frequently to children than adults with a viral in-
fection (77/209 (37%) versus 74/89 (83%), p < 0.001, (Fig. 1).
This difference was similar across different viral pathogens,
including influenza and RSV (Table 2). Within the microbio-
logically confirmed sub-cohort, similar percentages of antibi-
otic overuse were observed (50/145 (34%) children versus 50/
58 (86%) adults (Supplemental Fig. 1). Children receiving
antibiotics for viral RTI were more often admitted to the
Table 1 Baseline of bacterial and viral respiratory tract infections in
children and adults. Data are presented as N (%), mean (SD), or median
[IQR]. LRTI included pneumonia, acute bronchitis and bronchiolitis;
URTI included laryngitis, pharyngitis, otitis media, sinusitis, epiglottitis
and tonsillitis. Ill-appearing based on attending physician’s impression.
CRP C-reactive protein, ICU intensive care unit, COPD chronic
obstructive pulmonary disease, LRTI lower respiratory tract infection,
URTI upper respiratory tract infection
Children (N = 284) Adults (N = 232)
Age (years) 1.3 [0.6–3.0] 64.5 [52–75]
Male (sex) 167 (59) 131 (57)
Presence of comorbidity 125 (44) 199 (86)
Ill-appearing 113 (40) 114 (53)
Maximum temperature (°C) 39.2 (0.9) 38.6 (1.0)
Duration of symptoms (days) 3 (2) 4 (2)
Hospital admission 208 (75) 217 (94)
Hospitalisation duration, days 4 [3–8] 5 [3–8]
CRP (mg/L) at admission 16 [4–43] 34 [9–136]
Disease severity
Oxygen saturation (%) 95 [92–98] 94 [91–96]
Needed mechanical ventilation 31 (11) 3 (1)
Deaths 1 (1) 3 (1)
Admission site
Secondary care centre 198 (70) 173 (75)
Tertiary care centre 47 (16) 53 (23)
ICU 39 (14) 6 (2)
Country
The Netherlands 136 (48) 131 (56)
Israel 148 (52) 101 (44)
Clinical syndrome
COPD/asthma exacerbation 4 (1) 45 (19)
LRTI 150 (53) 172 (74)
URTI 130 (46) 15 (7)
Table 2 Appropriate and inappropriate antibiotic usage per virus. a.
Paediatric cohort. b. Adult cohort. Viral and bacterial diagnoses based
on expert panel diagnoses. Mixed infection was considered as bacterial.
Data shown represent the numbers of positive PCR of nasal swabs
performed for the study and N (%) of patients in this group receiving
antibiotics. RSV respiratory syncytial virus
a.
Paediatric Viral N = 209 Bacterial N = 75
Viruses detecteda Antibiotic usec Viruses detected Antibiotic use
Adenovirus 28 12(43) 2 2(100)
Bocavirus 22 7(32) 5 5(100)
Influenza virus 30 10(33) 6 6(100)
Rhinovirus 45 16(36) 17 16(94)
RSV 75 32(43) 23 22(96)
Otherb 26 11(42) 8 8(100)
b.
Adult Viral N = 89 Bacterial N = 143
Viruses detected Antibiotic usec Viruses detected Antibiotic use
Influenza virus 35 30(86) 17 16(94)
Rhinovirus 16 12(75) 6 6(100)
RSV 14 13(93) 4 4(100)
Otherd 11 10(91) 8 8(100)
a As some patients tested positive for more than one virus, the total number of detected viruses is higher than the number of patients. b Includes
coronavirus, human metapneumovirus, and parainfluenza virus. c Numbers of antibiotic usages are given per virus. As some patients tested positive
for more than one virus, the total antibiotic usage is different with respect to the numbers given in Fig. 1. d Includes adenovirus, bocavirus, coronavirus,
human metapneumovirus and parainfluenza virus
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ICU (p value 0.032) and had more often lower RTI (p value
0.001), compared with children not receiving antibiotics
(Table 4). Adults with viral RTI receiving antibiotics were
more often male (p value 0.033), had higher temperatures (p
value 0.004) and also had more often lower RTI (p value
0.003), compared with adults not receiving antibiotics
(Table 4). Among the patients with bacterial RTI (n = 218),
only one (1%) child and three (2%) adults were not treated
Table 3 Comparison of patients
with viral and bacterial reference
standards. a. Paediatric cohort. b.
Adult cohort. Viral and bacterial
diagnoses based on expert panel
diagnoses. Mixed infection was
considered as bacterial. Data are
presented asN (%), mean (SD), or
median [IQR]. CRP C-reactive
protein, ICU intensive care unit,
COPD chronic obstructive
pulmonary disease, LRTI lower
respiratory tract infection, URTI
upper respiratory tract infection
a. Paediatric cohort Viral N = 209 Bacterial N = 75 p value
Age (years) 1.2 [0.6–2.8] 1.3 [0.5–5.8] 0.102
Male sex 119 (57) 48 (64) 0.122
Presence of comorbidity 86 (41) 39 (52) 0.104
Ill-appearing 75 (36) 38 (51) 0.059
Maximum temperature (°C) 39.1 (0.9) 39.3 (0.9) 0.150
Duration of symptoms (days) 3 (2) 3 (2) 0.497
Hospital admission 144 (70) 64 (91) < 0.0001
Hospitalisation duration (days) 4 [3–6] 4 [2–16] 0.050
CRP (mg/L) at admission 13 [4–38] 22 [6–131] 0.001
Oxygen saturation (%) 96 [92–98] 95 [91–98] 0.523
Need mechanical ventilation 12 (6) 19 (25) < 0.0001
Admission site < 0.0001
Secondary care centre 152 (73) 46 (61)
Tertiary care centre 40 (19) 7 (9)
ICU 17 (8) 22 (29)
Country 0.291
The Netherlands 104 (50) 32 (43)
Israel 105 (50) 43(57)
Clinical syndrome < 0.0001
Asthma exacerbation 4 (2) 0 (0)
LRTI 110 (53) 55 (73)
URTI 95 (45) 20 (27)
b. Adult cohort Viral N = 89 Bacterial N = 143 p value
Age (years) 61 [46–72] 67 [53–75] 0.061
Male sex 46 (52) 85 (59) 0.247
Presence of comorbidity 79 (89) 120 (84) 0.304
Ill-appearing 38 (43) 76 (59) 0.023
Maximum temperature (°C) 38.3 (0.9) 38.7 (1.0) 0.015
Duration of symptoms (days) 4 (2) 4 (3) 0.495
Hospital admission 79 (89) 138 (97) 0.009
Hospitalisation duration (days) 4 [3–6] 6 [3–9] 0.010
CRP (mg/L) at admission 14 [4–43] 67 [16–193] < 0.0001
Oxygen saturation (%) 95 [91–96] 94 [92–97] 0.779
Needed mechanical ventilation 2 (2) 1 (1) 0.310
Admission site 0.007
Secondary care centre 71 (80) 102 (71)
Tertiary care centre 13 (15) 40 (28)
ICU 5 (5) 1 (1)
Country 0.376
The Netherlands 47 (53) 84 (59)
Israel 42 (47) 59 (41)
Clinical syndrome 0.001
COPD/asthma exacerbation 23 (26) 22 (15)
LRTI 55 (62) 117 (82)
URTI 11 (12) 4 (3)
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Table 4 Baseline of viral
respiratory tract infections
children and adults, antibiotics
versus no antibiotics. a. Paediatric
cohort. b. Adult cohort. Data are
presented asN (%), mean (SD), or
median [IQR]. LRTI included
pneumonia, acute bronchitis and
bronchiolitis; URTI included
laryngitis, pharyngitis, otitis
media, sinusitis and tonsillitis.
AB+ antibiotics prescribed, AB−
antibiotics not prescribed,CRPC-
reactive protein, ICU intensive
care unit, COPD chronic
obstructive pulmonary disease,
LRTI lower respiratory tract
infection, URTI upper respiratory
tract infection
a. AB+ (N = 77) AB− (N = 132) p value
Age (years) 1.0 [0.5–2.7] 1.2 [0.6–2.8] 0.945
Male sex 42 (55) 77 (58) 0.594
Presence of comorbidity 24 (31) 62 (47) 0.025
Ill-appearing 30 (39) 45 (35) 0.473
Maximum temperature (°C) 39.2 (0.9) 39.1 (0.8) 0.479
Duration of symptoms (days) 3 (2) 3 (2) 0.352
Hospital admission 60(79) 84 (65) 0.030
Hospitalisation duration (days) 5 [3–9] 3 [2–4] < 0.001
CRP (mg/L) at admission 14 [3–32] 10 [3–26] 0.294
Disease severity
Oxygen saturation, % 95 [88–97] 97 [93–99] 0.051
Needed mechanical ventilation 9 (12) 3 (2) 0.005
Death 0 (0) 0 (0) NA
Admission site 0.032
Secondary care centre 50 (65) 102 (77)
Tertiary care centre 16 (21) 24 (18)
ICU 11 (14) 6 (5)
Country 0.070
The Netherlands 32 (42) 72 (55)
Israel 45 (58) 60 (45)
Clinical syndrome 0.001
COPD/asthma exacerbation 0 (0) 4 (3)
LRTI 48 (62) 47 (36)
URTI 29 (38) 81 (61)
b. AB+ (n = 74) AB− (n = 15) p value
Age (years) 64 [47–75] 56 [51–60] 0.086
Male sex 42 (57) 4 (27) 0.033
Presence of comorbidity 66 (89) 13 (87) 0.778
Ill-appearing 34 (47) 4 (27) 0.156
Maximum temperature (°C) 38.5 (0.9) 37.8 (0.6) 0.004
Duration of symptoms (days) 4 (2) 3 (2) 0.478
Hospital admission 66 (89) 13 (87) 0.778
Hospitalisation duration (days) 4 [3–6] 4 [2–7] 0.805
CRP (mg/L) at admission 15 [5–45] 7 [3–35] 0.332
Disease severity
Oxygen saturation (%) 95 [91–96] 95 [91–98] 0.317
Needed mechanical ventilation 2 (3) 0 (0) 0.520
Death 1 (1) 0 (0) 0.651
Admission site 0.234
Secondary care centre 60 (81) 11 (73)
Tertiary care centre 9 (12) 4 (27)
ICU 5 (7) 0 (0)
Country 0.021
The Netherlands 35 (47) 12 (80)
Israel 39 (53) 3 (20)
Clinical syndrome 0.003
COPD/asthma exacerbation 14 (19) 9 (60)
LRTI 51 (69) 4 (27)
URTI 9 (12) 2 (13)
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with antibiotics (Supplemental Table 2). Dutch children re-
ceived mostly amoxicillin/clavulanate, whereas Israeli chil-
dren received mostly amoxicillin. Among adults, the most
p r e s c r i b ed an t i b i o t i c agen t s we r e amox i c i l l i n
(The Netherlands) and roxithromycin (Israel, Supplemental
Fig. 2). From patients with bacterial outcome, information
on antibiotic timing was available for 107 patients (49%). In
eight children (7%), antibiotics were prescribed > 72 h after
admission; seven of these children were admitted on the ICU.
All adults received antibiotics within 72 h after presentation.
Subgroup analysis
We analysed the Dutch (n = 267) and Israeli (n = 249) cohorts
separately (Supplemental Table 3). The children and adults in
the Dutch cohort more often had comorbidity, had higher CRP
concentrations and more often needed mechanical ventilation
compared to the Israeli patients. The proportion of bacterial
infections was similar in both countries. Antibiotic overuse in
children with viral infections was similar in the Dutch and
Israeli cohorts (32/104 (31%) versus 45/105 (43%), p =
0.07). In adults with viral infection, the proportion of patients
receiving antibiotics was lower in The Netherlands, when
compared with Israel (35/47 (74%) versus 39/42 (93%), p =
0.021). Of all 284 children, 39 (14%) children were admitted
to the ICU. Thirty-three (85%) ICU patients received antibi-
otics, 11 (33%) had viral infection. Six (2%) adults were ad-
mitted to the ICU; all received antibiotics. Five adult ICU
patients had viral infections, and one patient had a bacterial
infection. Influenza virus was detected in four of them.
Discussion
This convenience cohort of patients from the TTT biomarker
study is the first prospective study comparing the burden of
antibiotic misuse in both children and adults diagnosed with
RTI, using an expert panel adjudication as the reference stan-
dard [18]. We observed that antibiotic overuse was less com-
mon in children than in adults with a viral RTI (37% versus
83%), regardless of viral aetiology. Only one (1%) child and
three (2%) adults with bacterial infection were not treated with
antibiotics (i.e. underuse); all “untreated patients” were mild
cases with full spontaneous recovery.
As mentioned before, most studies that evaluated antibiotic
misuse rates are based on national datasets and classify infec-
tions, using general codes, such as the International
Classification of Diseases [4–6]. In the present prospective
study, using an expert panel reference standard, we confirmed
that antibiotic overuse in viral RTI is more prevalent among
adult patients. In our study, children less often had comorbid-
ity, appeared to be less ill at presentation and had lower a priori
probabilities of having a bacterial infection, compared with
adults. Physicians are more inclined to initiate antibiotic treat-
ment if the patient appears to be ill upon presentation, even if a
viral pathogen was detected, and do often not adhere to related
recommendations [19, 20]. Therefore, in addition to effective
diagnostic tests, education and prescribing feedback are need-
ed to reduce antibiotic overuse [21, 22].
The percentages of antibiotic underuse in our study were
low. In literature, underuse up to 31% for children with pneu-
monia has been described [23, 24]. Therefore, we performed a
post hoc analysis on a selection of patients for whom infor-
mation about the timing of antibiotic administration was avail-
able. We found delayed antibiotic prescribing (i.e. antibiotics
started > 72 h after admission) in only seven children who
were admitted to the ICU and one non-ICU child; there were
no delayed antibiotic prescriptions in adults. The expert panel
may have underestimated bacterial infections in patients re-
covering without antibiotics.
We included data from two different countries, both with
different healthcare systems, to make the results of this study
more generalizable.We did not observe significant differences
in overall antibiotic use between Dutch and Israeli children
and adults. However, existing literature shows that antibiotic
use is higher in Israel, compared with The Netherlands [25]. A
relatively high rate of antibiotic use in The Netherlands may
be related to the high proportion of severely ill patients (e.g.
more bacterial infection, more ICU admissions) in the Dutch
cohort.
A strength of our study is that the cohort comprised both
children and adults, enabling a direct comparison of findings
without any confounding issues related to the methodology. A
second strength is the thorough nature of our reference stan-
dard to distinguish viral from bacterial infections [16, 26].
Clinical suspicion confirmed by microbiological results is an
approach often employed in other studies as a reference stan-
dard, although this method can restrict the analysis to the easy-
to-diagnose patients and is not always technically applicable
to RTIs. Using an expert panel has the advantage of capturing
a wider spectrum of illness severities and, therefore, is more
likely to be generalizable to clinical practice [16, 27]. The
expert panel was provided with all available clinical informa-
tion, including information about the course of the disease, all
microbiological results (including study-specific multiplex
PCR on nasal swabs), and information from a 28-day fol-
low-up assessment. These information were not available to
the attending physicians when deciding to start antibiotics or
not.
A limitation of this study is that not all eligible patients
participated in this study for practical reasons (e.g. attending
physician did not have time to recruit the patient at the ED,
parents or patients did not want phlebotomy only for study
proposes), which may have introduced a selection bias in fa-
vour of more severely ill patients and could lead to an over-
estimation of antibiotic overuse. A second limitation is that,
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by design, patients with an inconclusive panel diagnosis (n =
88) were excluded, although it is notable that 98% of whom
were receiving antibiotics. Therefore, including these patients
would probably not change the results. Third, we collected a
nasal swab for every patient for the establishment of patient
diagnosis; other microbiological diagnostics (e.g. sputum and
blood cultures) were only performed if indicated for routine
care. Standardising more microbiological diagnostics might
have led to fewer inconclusive panel diagnoses. A fourth lim-
itation is that we do not have information on the use of influ-
enza and pneumococcal vaccines available. As a conse-
quence, we cannot exclude that information on vaccine history
of participants would have allowed for a more accurate panel
diagnosis. Fifth, we cannot exclude that some possible con-
founders (e.g. comorbidity, hospital admission and site-
specific protocols) might drive some of the difference in pre-
scribing practices between children and adults. Sixth, this
study is a sub-analysis of a convenience cohort of the TTT
biomarker study. Therefore, no sample size calculation for this
objective was made. Seventh, the presented proportions of
antibiotic misuse are based on expert panel diagnoses using
all available information after 28 days. We do not have a
reference standard diagnosis at the moment of presentation,
and therefore, analyses regarding antibiotic misuse using the
current available diagnostic tests could not be performed.
Eight, the eCRF used in this study does not include informa-
tion regarding negative microbiological test results. Ninth, the
inclusion criteria used in this study mostly includes symptoms
of lower RTI. This probably leads to an underestimation of the
proportion of patients with an upper RTI. However, several
patients did have symptoms of an upper RTI, and therefore,
we believe that the study cohort is representative for daily
practice. Finally, defined daily antibiotic dosages per 1000
patient days in France, Greece, the UK and the USA is 1.5–
3.3 times higher than in The Netherlands [28]. Due to the low
antibiotic prescription rates in The Netherlands, it is plausible
that antibiotic overuse will be even higher in other countries.
In conclusion, viral RTI is more common in children,
whereas antibiotic overuse is more common in adult patients
with RTI, supporting the need for better diagnostics to differ-
entiate between viral and bacterial infection across all ages.
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